PanVel Farmácias registers BRL 28m adjusted net profit in 2Q25, up 39.5% over 2Q24
PanVel Farmácias registra lucro líquido ajustado de BRL 28m no 2T25, aumento de 39,5% em relação ao 2T24
Intel ID : 421729
|
||||
Relevant Documents
| Press Release | 19 Aug 2025 | PanVel_Release_2T25_2025.pdf | PT |
|
| Intel ID | 421729 | |
| Value | EUR 4,43m | |
| Native Currency |
Brazilian Real (BRL)
Exchange Rate:  |
|
|
Financial Data - PanVel Farmácias
(31 Dec 2024) |
Revenue: EUR 771,57m EBITDA: EUR 63,30m Net Debt: EUR 53,27m Exchange Rate:
|
|
| Date |
|
|
| Country |  |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Primary Subsector (TTRSC) |
15.05.05 Drug Stores & Pharmacies (Primary) 15 Consumer Products & Services / 15.05 Distribution & Retail |
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
15.05.05 Drug Stores & Pharmacies 15 Consumer Products & Services / 15.05 Distribution & Retail |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.